Open Access Open Access  Restricted Access Subscription or Fee Access

Patents on Gastroretentive Drug Delivery System: An Overview

Lokesh P. Kothari, Atishkumar S. Mundada

Abstract


Background: Conventional oral dosage forms have poor bioavailability and recurrent dosing of the drug is needed to maintain the effective therapeutic concentration in the body. It may lead to poor patient compliance and fluctuations in the plasma level of drug especially in the chronic diseases and disorders. Origin: In outlook of this, to enhance the efficiency and bioavailability of the drug, gastroretentive drug delivery system is developed which can prolong the release and hence action of the drug in the body. Objective: The present review focus on recent patents and patent applications on gastroretentive drug delivery system. The various free patent search databases were used to collect and analyze the information on this oral drug delivery system. Results: Gastroretentive drug delivery system has been found to be of great importance due to their advantages over other oral dosage forms. These systems are formulated using various approaches and different types of release controlling polymers such as natural, semisynthetic, and synthetic polymers, and found to avoid the limitations of conventional oral dosage forms. Conclusion: Gastroretentive drug delivery system has potential especially in case of the chronic diseases and lifestyle disorders. These systems have unique commercial advantages which will sustain the interest of both the researchers and the pharmaceutical companies.


Keywords


Controlled release systems, delayed release systems, gastroretentive system, modified release systems, oral dosage, sustained release systems

Full Text:

PDF

References


Amul M, Pinky G. Gastroretentive drug delivery system: a review. Int J Drug Dev & Res. 2012; 4(4): 28–39.

Shaikh S. Recent trends in gastroretentive drug delivery systems. Int J Pharmaceut Res. & Dev. 2013; 5: 80–88.

Sunil K, Faraz J, Meenu R, et al. Gastroretentive drug delivery system: features and facts. Int J Res in Pharm and Biomed Sci. 2012; 3(1): 125–136.

Sravya K, Kavitha K, Rupesh KM, et al. Gastroretentive drug delivery systems: a review. Res J Pharm, Biol and Chem Sci. 2012; 3(3): 965–980.

6.Singh BN, Kim HK. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Rel. 2000; 63(3): 235–259.

7.Vinod KR et al. Approaches for gastroretentive drug delivery systems. Int J Appl Biol and Pharm Tech. 2010; 1(2): 589–601.

5.Klausner EA, Lavy E, Friedman M, et al. Expandable gastroretentive dosage forms. J Control Rel. 2003; 90(2): 143–162.

Bhalla N, Goswami M. Floating drug delivery system. Int J Pharm Res & Allied Sci. 2012; 1(4): 20–28.

Carvalho FC, Bruschi ML, Evangelista RC, et al. Mucoadhesive drug delivery systems. Brazilian Journal of Pharmaceutical Sciences. 2020; 46(1): 1–7.

Berner B, Chen C. GR dosage form extended-release of acamprosate. US9801816. 2017.

Kumar V, Shavej A, Singh RB. GR Tablets. US9393205. 2016.

Berner B, Louie-Helm J, Shell JW. Gastroretentive oral dosage form with restricted drug release in lower GIT.US 7976870. 2011.

Markus Krumme. Expandable GR therapeutically system for prolonged gastric retention time. US 6776999. 2004.

Gusler G, Berner B. Optimal polymer mixtures for gastric retentive tablets. US 6723340. 2004.

Shell JW, Louie-Helm J, Markey M. Dosage form extending the duration of drug release in the gastric region during fed mode. US 6635280. 2003.

Wong P, Dong LC, Edgren DE, et al. Prolonged-release drug delivery device adapted for gastric retention. US 6548083. 2003.

Berner B, Louie-Helm J. Tablets shape to enhance gastric retention. US 6488962. 2002.

Shell JW, Louie-Helm J. Gastroretentive, an oral dosage form for CR of sparingly soluble drugs. US 5972389. 1999.

Conte U, Maggi L. Pharmaceutical tablet exhibiting high volume increase when gets in contact with gastric fluids. US 5780057. 1998.

Larry J Caldwell, Colin R, et al. Gastric retaining drug delivery device for controlled delivery of drugs. US 4767627. 1998.

Jahagirdar HA, Kulkarni R, Kulkarni S. A pharmaceutical composition for the GI drug delivery system. US 8974825. 2015.

Peter William, Dettmar PW, Dickson PA, Hampson FC, et al. Mucoadhesive granules of carbomer suitable for oral administration of drugs. US 6306789. 2001.

Paul M, Victor Gilis V. Mucoadhesive granules of carbomer suitable for oral administration of drugs. US 6303147. 2001.

Rault I, Pichon G. Mucoadhesive for CR of the active principle. US 5900247. 1999.

Giancarlo S, Giuseppe B, Giovanni S. Pharmaceutical CR composition with bioadhesive properties. US 5472704. 1995.

Castan C, Philippe C. Controlled release floating pharmaceutical compositions. US 9561179. 2017.

Grenier P, Nhamias A, Vergnault G. Floating GR dosage form. US 9314430. 2016.

Muthusamy R, Kulkarni MG. GR extended release composition of the therapeutic agent. US 8808669. 2014.

Singh A, Singh S, Puthli S, Tandale R. Programmatic buoyant delivery technology. US 8277843. 2012.

Illum L, Ping H. Gastroretentive controlled-release microspheres. US 6207197. 2001.

Walter M, Edzard A. Floating system for oral therapy. US 5626876. 1997.

Franz MR, Oth MP. Sustained release bilayer buoyant dosage form. US 5232704. 1993.

Kumar V, Ahmad S, Singh RM, et al. Stabilized GR tablets of pregabalin. US 20160338949. 2016.°

Kumar V, Ahmad S, Singh RM, et al. Osmotic floating tablets. US 20150231084. 2015.

Navon N, Moor E, Kirmayer D, et al. GR dosage form for carbidopa. US 20150366832. 2015.

Bakan DA, Jitpraphai W, Newhard SB, et al. GR dosage form of Doxycycline. US 9119793. 2015.

Mohammad H. GRDDS comprising an extruding hydratable polymer. US 8586083. 2013.

Edgren DE, Jao F, Wong PS. Gastric retaining dosage form having multiple layers. US 6797283. 2004.

Wong PS, Edgren DE. The gastric retaining liquid dosage form. US 6635281. 2003.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Trends in Drug Delivery